Le Lézard
Classified in: Health, Science and technology, Business
Subjects: BOARD OF DIRECTORS, SHAREHOLDER RIGHTS PLANS

AccuStem Sciences, Inc. Announces Chairman Purchase of Shares


LONDON and PHOENIX, Nov. 22, 2022 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman of the Board, Mr. Gabriele Cerrone, has notified the Company that he has recently purchased an additional 24,500 ACUT shares in the open market. This brings his total holding to 3,855,723 shares.

About AccuStem

AccuStem is a clinical stage diagnostics company dedicated to optimizing outcomes and quality of life for all patients with cancer. We plan to drive innovation in healthcare by offering proprietary molecular testing that addresses unmet clinical needs from cancer screening through treatment and monitoring. By interrogating novel disease pathways, such as tumor "stemness," we believe our tools will help care teams better understand the biology of each patient's cancer, leading to more informed decision making. For more information, please visit www.accustem.com.

Media Contact:
Jeff Fensterer
Phone: 415-640-6010
Email: [email protected]

Investor Contact:
Wendy Blosser
Email: [email protected]



These press releases may also interest you

at 14:56
Egret Therapeutics, a clinical-stage biotechnology company focused on developing transformative therapies for neurological conditions, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)...

at 13:00
Third Tier Wealth Management, offering financial planning & investment management, today announced that they have entered into an agreement to work with Buckingham Strategic Partners (BSP), a national financial services firm with their main office in...

at 11:45
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of ESS Tech Inc. between August 11, 2022 and December 7, 2022, both dates inclusive (the "Class Period"), of the important March 13, 2023 lead plaintiff...

at 11:00
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Silvergate Capital Corporation ("Silvergate" or the "Company") and reminds investors of the February 6, 2023 deadline to seek the role of lead...

at 11:00
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Super Micro Computer Inc.  ("Super Micro" or the "Company") ....

at 09:00
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against NewAge, Inc. ("NewAge" or the "Company") and reminds investors of the February 6, 2023 deadline to seek the role of lead plaintiff in a federal...



News published on 22 november 2022 at 07:00 and distributed by: